Prosecution Insights
Last updated: November 04, 2026
Application No. 19/296,589

SYSTEM AND METHOD FOR RANKING OPTIONS FOR MEDICAL TREATMENTS

Non-Final OA §101§DOUBLEPATENT
Filed
Aug 11, 2025
Priority
Jan 13, 2020 — continuation of 11/227,680 +1 more
Examiner
CHNG, JOY POH AI
Art Unit
3686
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
Prxcision Inc.
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
2y 2m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
385 granted / 635 resolved
+8.6% vs TC avg
Strong +19% interview lift
Without
With
+19.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
21 currently pending
Career history
671
Total Applications
across all art units

Statute-Specific Performance

§101
31.9%
-8.1% vs TC avg
§103
33.9%
-6.1% vs TC avg
§102
9.7%
-30.3% vs TC avg
§112
14.8%
-25.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 635 resolved cases

Office Action

§101 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status Of Claims This action is in reply to the application filed on 08/11/2025. Claims 1-19 are currently pending and have been examined. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Omum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321 (c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 1-19 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 12,387,828. Although the conflicting claims are not identical, they are not patentably distinct from each other because claims 1-19 of the instant pending application omit certain steps of claims 1-9 in the 12,387,828 patent. Therefore, claims 1-19 are prima facie obvious of claims 1-9 in the 12,387,828 patent, because it would have been obvious to omit certain steps with the motivation for providing systems and methods for determining a probability of attaining a PK-PD target associated with efficacy for a patient. Claims 1-19 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of copending Application No. 18/753,444. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-19 of the instant pending application omit certain steps of claims 1-19 in the copending Application No. 18/753,444. Therefore, claims 1-19 are prima facie obvious of claims 1-19 in the copending Application No. 18/753,444, because it would have been obvious to omit certain steps with the motivation for providing systems and methods for determining a probability of attaining a PK-PD target associated with efficacy for a patient. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-19 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. Claims 1-19: Step 1 Claims 1-17 are drawn to a computer-implemented method for determining a probability of attaining a PK-PD target associated with efficacy for a patient, which is within the four statutory categories (i.e. process). Claim 18 is drawn to a computer system for determining a probability of attaining a PK-PD target associated with efficacy for a patient, which is within the four statutory categories (i.e. machine). Claim 19 is drawn to a computer program product for determining a probability of attaining a PK-PD target associated with efficacy for a patient, which is within the four statutory categories (i.e. machine). Claims 1-19: Step 2A Prong One Claim 1 recites determining, that a trigger event related to a patient, wherein the patient record comprises an order for a current drug regimen, has occurred in a health record based on obtaining the notification, obtaining, from one or more medical records, descriptive information relating to a patient, the descriptive information comprising one or more data elements selected from the group consisting of: an infection acquired by the patient, a pathogen isolated from the patient, a creatinine clearance of the patient, a weight of the patient, and a height of the patient; based on the one or more drug therapies, selecting a pharmacokinetic model; applying, the pharmacokinetic model and utilizing the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection; generating, rankings, for each of the one or more drug therapies, by ordering each probability of attaining the PK-PD target associated with efficacy for the patient with the infection, for each of the one or more drug therapies, for the one or more drug therapies, wherein the rankings comprise a ranked list with the probability of attaining a PK-PD target associated with efficacy for the patient with the infection for each of the one or more drug therapies, ranked in order of predicted efficacy; determining, based on the rankings, if the current drug regimen comprises a probability above a preconfigured threshold; and on the determining and the rankings, generating a recommendation for a new order. Claims 18 and 19 recite similar limitations. These limitations, as drafted, given the broadest reasonable interpretation, but for the recitation of generic computer components, encompass managing personal behavior by manually following rules or instructions, which is a subgrouping of Certain Methods of Organizing Human Activity. But for the recitation of generic computer components, these limitations encompass a user determining, that a trigger event related to a patient, wherein the patient record comprises an order for a current drug regimen, has occurred in a health record based on obtaining the notification, obtaining, from one or more medical records, descriptive information relating to a patient, the descriptive information comprising one or more data elements selected from the group consisting of: an infection acquired by the patient, a pathogen isolated from the patient, a creatinine clearance of the patient, a weight of the patient, and a height of the patient; based on the one or more drug therapies, selecting a pharmacokinetic model; applying, the pharmacokinetic model and utilizing the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection; generating, rankings, for each of the one or more drug therapies, by ordering each probability of attaining the PK-PD target associated with efficacy for the patient with the infection, for each of the one or more drug therapies, for the one or more drug therapies, wherein the rankings comprise a ranked list with the probability of attaining a PK-PD target associated with efficacy for the patient with the infection for each of the one or more drug therapies, ranked in order of predicted efficacy; determining, based on the rankings, if the current drug regimen comprises a probability above a preconfigured threshold; and on the determining and the rankings, generating a recommendation for a new order. These steps could be carried out manually by a user following rules or instructions, which is a subgrouping of Certain Methods of Organizing Human Activity. Claims 18 and 19 recite similar limitations. Claims 2-17 incorporate the abstract idea identified above and recite additional limitations that expand on the abstract idea, but for the recitation of generic computer components. Claims 2-3 further define the determining. Claims 4-5 further define generating the recommendation. Claims 6-7 further define the transmitting. Claim 8-9 further define the trigger event. Claim 10 further defines retaining the recommendation. Claim 11 further defines generating or updating a base model. Claim 12 further defines the data. Claim 13 further defines selecting the pharmacokinetic model. Claim 14 further defines obtaining additional information. Claim 15 further defines the patient specific response modifiers. Claims 16-17 further define determining that the trigger event has occurred. Therefore, these claims are similarly drawn to Certain Methods of Organizing Human Activity. Claims 1-19: Step 2A Prong Two This judicial exception is not integrated into a practical application because the remaining elements amount to no more than general purpose computer components programmed to perform the abstract ideas along with insignificant, extra-solution data gathering activity, and adding limitations similar to adding the words “apply it” to the abstract idea. Claim 1 recites the additional elements that the computer-implemented system comprises one or more processors and electronic health record system. Claim 18 recites additional elements of a computer system comprising a memory and one or more processors to perform a method. Claim 19 recites additional elements of a computer program product comprising a computer readable storage medium storing instructions for execution by one or more processors. Claims 1-19, directly or indirectly, recite the following generic computer components: “processors”, “computer system,” and “computer program product” which are similar to adding the words “apply it” to the abstract idea. The written description discloses that the recited computer components encompass generic components including “FIG. 1 is a computer system 100 configured to perform at least one aspect of an embodiment of the present invention. In the embodiment of FIG. 1, software 10 is executed by at least one processor on a computer, termed a base computer 12 in FIG. 1 for clarity. The terms software, program code, computer program code, code, computer program product, and executable instructions, are used interchangeably throughout this application“ (see at least Paragraph [0033]), “The software comprises code that is accessible to the processor and executable by at least one processor of the computer 12. The software can be stored on a memory on the physical computer 12, and/or in a memory and/or on removable media accessible to the computer“ (see at least Paragraph [0034]) and “As will be appreciated by one skilled in the art, aspects of the technique may be embodied as a system, method or computer program product. Accordingly, aspects of the technique may take the form of an entirely hardware embodiment, an entirely software embodiment (including firmware, resident software, micro-code, etc.) or an embodiment combining software and hardware aspects that may all generally be referred to herein as a “circuit,” “module” or “system.” Furthermore, aspects of the technique may take the form of a computer program product embodied in one or more computer readable medium(s) having computer readable program code embodied thereon” (see at least Paragraph [0042]). Although the additional elements limits the identified judicial exceptions, this type of limitation merely confines the use of the abstract idea to a particular technological environment, and thus fails to add an inventive concept to the claims. See MPEP 2106.05 (h). As set forth in the 2019 Eligibility Guidance, 84 Fed. Reg. at 55 “merely include[ing] instructions to implement an abstract idea on a computer” is an example of when an abstract idea has not been integrated into a practical application. Claims 1-19: Step 2B The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception because as discussed above with respect to integration into a practical application, the additional elements are recited at a high level of generality, and the written description indicates that these elements are generic computer components. Using generic computer components to perform abstract ideas does not provide a necessary inventive concept. See Alice, 573 U.S. at 223 (“mere recitation of a generic computer cannot transform a patent-ineligible abstract idea into a patent-eligible invention.”). As explained above, the generic computer components and machine learning are at best the equivalent of merely adding the words “apply it” to the judicial exception. Receiving and transmitting data over a network (i.e. receiving and communicating data or signals) has been recognized as well-understood, routine, and conventional activity of a general-purpose computer (see MPEP 2106.05(d) and buySAFE, Inc. v. Google, Inc., 765 F.3d 1350, 1355, 112 USPQ2d 1093, 1096 (Fed. Cir. 2014)). Gathering and analyzing information using conventional techniques and displaying the result has also been found to be insufficient to show an improvement to technology, (see MPEP 2106.05(a) and TLI Communications, 823 F.3d at 612-13, 118 USPQ2d at 1747-48). Insignificant, extra solution, data gathering activity has been found to not amount to significantly more than an abstract idea (see MPEP 2106.05(g) and Electric Power Group, LLC v. Alstom S.A., 830 F.3d 1350, 1354-55, 119 USPQ2d 1739, 1742 (Fed. Cir. 2016)). Therefore, the high-level recitation of an output of results also fails to include additional elements that are sufficient to amount to significantly more than the judicial exception. Therefore, whether considered alone or in combination, the additional elements do not amount to significantly more than the abstract idea. Allowable Subject Matter The claims are allowable if rewritten to overcome the 35 U.S.C. 101 rejections, and if the double patenting rejection is overcome. The following is an examiner’s statement of reasons for allowances: The claims are allowable for similar reasons to the copending Application No. 18/753,444. The most remarkable prior art of record and considered pertinent to applicant’s disclosure is as follows: Ziegler et al.: U.S. Patent 8,688,469, discloses a system and method for identifying a prospective clinical therapy for a prospective patient having a medical device. Syroid et al.: U.S. Patent Application Publication U.S. 2012/0197188 A1, discloses drug delivery models, displays and systems to provide a clinical with readily intuitive information about the effects of one or more drugs on a subject. Interactive features may provide a subject-specific model of the expected and predicted effects of one or more drugs on the subject. Fleming et al.: U.S. Patent 10,490,302, discloses systems and methods for improving patient access to medical therapies Von Hoff et al.: U.S. Patent 8,831,890, discloses system and method for determining individualized medical intervention for a disease state Yeaman et al.: U.S. Patent Application Publication U.S. 2014/0329740 A1, discloses method for preventing or treating various infectious diseases Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joy Chng whose telephone number is 571.270.7897. The examiner can normally be reached on Monday-Friday, 9:00am-5:00pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, JASON DUNHAM can be reached on 571.272.8109. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866.217.9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOY CHNG/ Primary Examiner, Art Unit 3686
Read full office action

Prosecution Timeline

Aug 11, 2025
Application Filed
Sep 28, 2026
Non-Final Rejection mailed — §101, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12784920
WELLNESS SYSTEM
3y 0m to grant Granted Nov 03, 2026
Patent 12784918
Medical Decision Support System with Rule-Driven Interventions
2y 4m to grant Granted Nov 03, 2026
Patent 12763217
Computer Implemented Method for Determining a Heart Failure Status of a Patient, Training Method and System
2y 5m to grant Granted Oct 13, 2026
Patent 12744120
PHYSIOLOGICAL PARAMETER ALARM DELAY
2y 1m to grant Granted Sep 22, 2026
Patent 12738366
CLINICIAN USER INTERFACE
3y 4m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
80%
With Interview (+19.0%)
3y 5m (~2y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 635 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month